discovery phase, where rapid diagnostics would enable the development and clinical adoption of pathogen-targeted antibiotics. The wide genetic diversity of pathogenic bacteria ( 16) has been an obstacle to the development of broad-spectrum drugs. Molecules that target individual pathogens of particular importance should be easier to identify and optimize for selectivity and toleration, and more rapid to develop in targeted patient populations. One such pathogen could be Acinetobacter baumannii, which is often resistant to current treatments and is associated with high mortality rates ( 17) . Such narrowly targeted drugs should be premium priced, as they would be used to treat a small number of patients with serious, otherwise untreatable infections ( 18) .
Rapid molecular diagnostics paired with pathogen-targeted antibiotics would usher in an era of "personalized health care" for patients suffering from bacterial infections. Most patients would continue to be treated with older, inexpensive, and still effective antibiotics. Rapid diagnostics could help identify those patients requiring new-generation drugs that target highly pathogenic or resistant strains, limiting unnecessary use and slowing the emergence of resistance: altogether, a more sustainable practice, both in terms of clinical care and antibiotic stewardship. ■ ACKNOWLEDGMENTS I thank P. Bradford for critical review. The views expressed in this article are those of the author and do not necessarily represent the views of, nor should be attributed to, AstraZeneca.
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A fter many years out of the limelight, antimicrobial resistance (AMR) in bacteria is firmly back on the international political and scientific agenda ( 1, 2) . The potential impact of AMR on hospital-acquired bacterial infections such as Staphylococcus aureus and Acinetobacter baumannii in higher-income countries has created both fear and a surge of motivation aimed at providing new solutions for the problem ( 3, 4) . The political will and momentum to tackle AMR lies in higher-income countries, but the medical, social, and economic effects of AMR are likely to be felt more in lower-income countries, particularly those in South and Southeast Asia and in subSaharan Africa. The identification and development of new drugs is a potential solution but is challenging and costly; any novel therapies introduced into low-income settings without a suitable infrastructure to understand and prevent the rapid development of resistance will likely be expensive and futile.
In many countries at the lower end of the global economic ladder, infections caused by multidrug resistant (MDR) and extended drug resistant (XDR) bacteria are a common reality. Variants of bacterial pathogens carrying novel AMR mechanisms disproportionately originate in lower-income countries, with downstream consequences both within and outside the region in which they appear. This phenomenon was highlighted in 2008 by the emergence of the carbapenem resistance-inducing New Delhi metallo-β-lactamase-1 (NDM-1) ( 5). This gene induces broad resistance against carbapenems and other β-lactams and was first identified in a Klebsiella pneumoniae strain isolated from a Swedish national upon returning from India. The plasmids carrying this gene have since become common and are having dramatic impact on the efficacy of carbapenems and other β-lactams in hospitals. A recent report described hospital outbreaks of Klebsiella pneumoniae in children on highdependency wards in South Asia ( 6) . These outbreaks were caused by particularly virulent variants, which induced a rapid-onset bacteremia resulting in a 75% mortality rate in the infected children. The presence of NDM-1 within an already broadly antimicrobial-resistant and highly virulent strain severely restricted the treatment options, with a direct impact on patient mortality. This and many other studies have shown that AMR genes thrive in low-income settings and can combine effortlessly with other resistance mechanisms. Further, these wideranging combinations of drug resistance mechanisms can be maintained and then transferred within and between numerous bacterial species.
The reasons behind the apparent amplification of the current risk in AMR infections in lower-income countries are intricate and occasionally geographically driven, but there are common themes that highlight the key issues. First, the bacterial pathogens found in lower-income settings (such as typhoid fever and tuberculosis meningitis) typically cause more severe infections than those in higher-income countries. Second, antimicrobials are widely available for purchase in the community without medical consultation and without government policies restricting their use; community overuse and underdosing are common. Third, the medical treatment, range of available antimicrobials, and health care facilities are generally better in higher-income countries; the risk associated with having a poor outcome after infection with a resistant pathogen is therefore greater in lower-income countries. Fourth, very few patients receive any form of conclusive diagnostic testing before, or indeed after, they are treated with an empiric antimicrobial regime. The effects of antimicrobial resistance will be felt most acutely in lower-income countries SCIENCE sciencemag.org third-generation cephalosporin without diagnostic testing. Finally, the same classes of compounds used to treat human infections are routinely supplemented into animal feed to increase livestock production and, ultimately, agricultural profitability.
In contrast, higher-income countries have guidelines for antimicrobial usage in animals, diagnostic laboratories, antimicrobial stewardship schemes, and better health care structures on which to create sustainable AMR programs. Such infrastructures and awareness mean that AMR infections are less common in high-income countries than in low-income countries and are mainly limited to health care settings. Additionally, when an issue with a particular AMR pathogen is identified in health care settings, it can be tackled, as exemplified by the dramatic reduction through health care interventions of methicillin-resistant Staphylococcus aureus (MRSA)-associated infections throughout the health care structure in England and Wales ( 7) .
Advances in genome sequencing technologies and analysis techniques have laid bare the extent of the AMR problem and have begun to explain the evolutionary mechanisms behind the maintenance and spread of AMR genes and AMR-inducing mutations. Phylogenetic reconstructions prove that the recent evolutionary histories of numerous bacterial pathogens from lower-income settings have been shaped almost exclusively by sustained antimicrobial exposure. The ability to timestamp the emergence of specific lineages and reconstruct pivotal evolutionary events enables identification the key drivers of new founder populations ( 8) .
For example, genomic data have shown that Vibrio cholerae, the major cause of epidemic diarrhea disease in low-income settings, has radiated from the Bay of Bengal in several pandemic waves (see the map) ( 9) . These waves have been shaped by the acquisition of an SXT (chromosomal gene island) element that encodes a whole host of AMR determinants, including those active against sulfamethoxazole, trimethoprimsulfate, chloramphenicol, streptomycin, and β-lactams. The clinical impact of AMR in cholera is poorly defined; however, many cholera patients are treated with empirical rehydration therapy and antimicrobials. Therefore, AMR in Vibrio cholerae is likely to play a role in the duration of the infection and the asymptomatic transmission of the pathogen into the community after cessation of symptoms.
Typhoid fever serves as another good example. It is a common bloodstream infection caused by the bacterium Salmonella Typhi (see the image). Before the antimicrobial era the disease had a ~20% mortality rate, which was dramatically reduced when effective therapies were introduced. After the emergence of MDR strains, fluoroquinolones became the recommended therapy in the 1990s, but reduced susceptibility to this group of compounds emerged almost immediately. Genome sequencing has shown that the mutations that catalyze resistance to fluoroquinolones emerged in numerous lineages and on several occasions; today, one lineage with reduced susceptibility to fluoroquinolones has nearly replaced all other variants ( 10, 11) . The spread of this lineage is clinically relevant, because increasing resistance to fluoroquinolones correlates precisely with likelihood of treatment failure during fluoroquinolone therapy ( 12) . We are on the verge of widespread resistance to fluoroquinolones in typhoid fever ( 13) ; there are few alternatives, and thus a very real possibility of a return to conditions like those in the pre-antimicrobial era.
AMR in dangerous bacterial pathogens such as Salmonella Typhi, Vibrio cholerae, and Klebsiella pneumoniae in low-income countries can only be tackled through a multifaceted approach that includes drug discovery programs, sustainable antimicrobial usage policies, and disease prevention strategies including immunization, improved sanitation, hospital infection control, and improved diagnostics. New-generation vaccines and diagnostics for many bacterial infections common in developing countries are under exploration, but there are currently no programs aimed at developing novel therapeutic agents specifically to treat dangerous bloodstream infections caused by pathogenic organisms such as Salmonella Typhi and Klebsiella pneumoniae.
There is an urgent need for those studying infections caused by AMR bacteria in low-income settings to establish connections with drug discovery groups and pharmaceutical companies in high-income countries ( 14) . Examples such as the Tuberculosis Drug Accelerator program ( 15) 
The three waves of pandemic Vibrio cholerae
The global spread of AMR genes. Vibrio cholerae, the bacterium that causes cholera, exemplifies how pathogenic bacteria can spread globally. Since the 1930s, the organism has spread in multiple waves from the Bay of Bengal. Waves 2 and 3 can be characterized by a SXT drug resistance-carrying gene island ( 9) .
Electron micrograph of Salmonella Typhi, the agent of typhoid fever. Widespread multidrug resistance in this bacterium raises the specter of a return to conditions resembling those of the pre-antimicrobial era.
sciencemag.org SCIENCE successful. These pioneering initiatives are beginning to link pharmaceutical companies, academia, and disease experts across the "gene to bedside" spectrum in the locations where these diseases have the greatest impact. The MMV provides free, open access to a range of compounds with activity against a range of pathogens for independent researchers to screen, with users requested to publish their data in the public domain, thus continuing the drug development research cycle ( 17) .
The impact of bacterial AMR in lowincome countries is severe and likely to worsen. New antimicrobial agents may provide some respite against AMR and infections caused by such drug-resistant pathogens. However, introducing novel broad-range antimicrobials into the current melee of antimicrobial use and misuse in lower-income countries would only have a short-term limited impact on infections caused by potentially life-threatening pathogens. Restricting the use of the same classes of antimicrobial compounds in animals and humans has to be an immediate priority, including a direct ban of any new antimicrobials developed for treating infections in humans. Lastly, new antimicrobial agents should only be administered to those who really need them. This means that the current capacity to perform microbial diagnostics and downstream antimicrobial susceptibility testing needs to be greatly improved, alongside the development of rational prescribing practice. ■
